{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:38:33Z","timestamp":1790635113158,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T00:00:00Z","timestamp":1618876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The primary study objective of this retrospective academic memory clinic-based observational longitudinal study was to investigate the prognostic value of a cerebrospinal fluid (CSF)-based ATN classification for subsequent cognitive decline during the 3\u00a0years following lumbar puncture in a clinical, real-life setting. The secondary objective was to investigate the prognostic value of CSF biomarkers as continuous variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data from 228 patients (median age 67 (47\u201385) years), who presented at the Neurology Memory Clinic UZ\/KU Leuven between September 2011 and December 2016, were included with a follow-up period of up to 36\u2009months. Patients underwent a CSF AD biomarker test for amyloid-beta 1\u201342 (A\u03b2<jats:sub>42<\/jats:sub>)<jats:sub>,<\/jats:sub> hyperphosphorylated tau (p<jats:sub>181<\/jats:sub>-tau) and total tau (t-tau) in the clinical work-up for diagnostic reasons. Patients were divided into ATN classes based on CSF biomarkers: A\u03b2<jats:sub>42<\/jats:sub> for amyloid (A), p<jats:sub>181<\/jats:sub>-tau for tau (T), and t-tau as a measure for neurodegeneration (N). Based on retrospective data analysis, cognitive performance was evaluated by Mini Mental State Examination (MMSE) scores every 6\u2009months over a period up to 36\u2009months following the lumbar puncture. The statistical analysis was based on linear mixed-effects modeling (LME).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The distribution in the current clinical sample was as follows: A\u2212\/T\u2212\/N\u2212 32.02%, A+\/T\u2212\/N\u2212 33.33%, A+\/T+\/N+\u200917.11%, A+\/T\u2212\/N+\u200911.84%, A\u2212\/T\u2212\/N+\u20094.39%, A\u2212\/T+\/N+\u20091.32% (3 cases), with no cases in the A\u2212\/T+\/N\u2212 and A+\/T+\/N\u2212 class. Hence, the latter 3 classes were excluded from further analyses. The change of MMSE relative to A\u2212\/T\u2212\/N\u2212 over a 36-month period was significant in all four ATN classes: A+\/T+\/N+\u2009=\u2009\u2212\u20094.78 points on the MMSE; A\u2212\/T\u2212\/N+\u2009=\u2009\u2212\u20094.76; A+\/T\u2212\/N+\u2009=\u2009\u2212\u20092.83; A+\/T\u2212\/N\u2212\u2009=\u2009\u2212\u20091.96. The earliest significant difference was seen in the A+\/T+\/N+ class at 12\u2009months after baseline. The effect of ATN class on future cognitive decline was confirmed for a different set of CSF thresholds. All individual baseline CSF biomarkers including the A\u03b2<jats:sub>42<\/jats:sub>\/t-tau ratio showed a significant correlation with subsequent cognitive decline, with the highest correlation seen for A\u03b2<jats:sub>42<\/jats:sub>\/t-tau.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ATN classification based on CSF biomarkers has a statistically significant and clinically relevant prognostic value for the course of cognitive decline in a 3-year period in a clinical practice setting.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13195-021-00817-4","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T12:21:36Z","timestamp":1618921296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Prognostic value of amyloid\/tau\/neurodegeneration (ATN) classification based on diagnostic cerebrospinal fluid samples for Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-4502","authenticated-orcid":false,"given":"Koen","family":"Delmotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Schaeverbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Poesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,20]]},"reference":[{"key":"817_CR1","volume-title":"Dementia in Europe yearbook. Estimating the prevalence of dementia in Europe","author":"Alzheimer Europe","year":"2019","unstructured":"Alzheimer Europe. Dementia in Europe yearbook. Estimating the prevalence of dementia in Europe 2019;"},{"issue":"7","key":"817_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/WNL.34.7.939.","journal-title":"Neurology."},{"key":"817_CR3","volume-title":"revising the NINCDS-ADRDA criteria","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Rey Cummings J, et al. revising the NINCDS-ADRDA criteria. 2007."},{"key":"817_CR4","volume-title":"Position Paper Revising the defi nition of Alzheimer\u2019s disease: a new lexicon","author":"B Dubois","year":"2010","unstructured":"Dubois B, Hospital D, Dubois B, Feldman HH, Jacova C, rey Cummings JL, et al. Position Paper Revising the defi nition of Alzheimer\u2019s disease: a new lexicon, vol. 9; 2010."},{"issue":"3","key":"817_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"817_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"817_CR7","volume-title":"VIEWS & REVIEWS A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers","author":"CR Jack","year":"2016","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. VIEWS & REVIEWS A\/T\/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. 2016."},{"issue":"3","key":"817_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003.","journal-title":"Alzheimers Dement"},{"key":"817_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack","year":"2010","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurology. 2010;9:119\u201328 Lancet Publishing Group.","journal-title":"Lancet Neurology"},{"issue":"7","key":"817_CR10","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archneurol.2011.3405","volume":"69","author":"CR Jack","year":"2012","unstructured":"Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012;69(7):856\u201367. https:\/\/doi.org\/10.1001\/archneurol.2011.3405.","journal-title":"Arch Neurol"},{"key":"817_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/S1474-4422(09)70330-8","volume":"9","author":"RC Petersen","year":"2010","unstructured":"Petersen RC. Alzheimer\u2019s disease: progress in prediction. Lancet Neurol. 2010;9:4\u20135 Lancet Publishing Group.","journal-title":"Lancet Neurol"},{"key":"817_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131\u201344.","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"817_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. Mini-mental state - a practical method for grading the cognitive state of patients for the clinician. J psychiat Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J psychiat Res"},{"key":"817_CR14","doi-asserted-by":"crossref","unstructured":"Adamczuk K, Schaeverbeke J, Vanderstichele HMJ, Lilja J, Nelissen N, Van Laere K, et al. Diagnostic value of cerebrospinal fluid A\u03b2 ratios in preclinical Alzheimer\u2019s disease. Alzheimers Res Ther. 2015;7(1):75.","DOI":"10.1186\/s13195-015-0159-5"},{"issue":"2","key":"817_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v048.i02","volume":"48","author":"Y Rosseel","year":"2012","unstructured":"Rosseel Y. lavaan: an R package for structural equation modeling. R package version 0.5-15 http:\/\/lavaan.org. J Stat Softw. 2012;48(2):1\u201336.","journal-title":"J Stat Softw"},{"issue":"1","key":"817_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0362-2","volume":"10","author":"I Baldeiras","year":"2018","unstructured":"Baldeiras I, Santana I, Leit\u00e3o MJ, Gens H, Pascoal R, T\u00e1buas-Pereira M, et al. Addition of the A\u03b242\/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer\u2019s disease dementia in mild cognitive impairment. Alzheimers Res Ther. 2018;10(1):1\u201315.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"817_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M, H\u00fcll M, Hampel H, Kessler H, Fr\u00f6lich L, Schr\u00f6der J, Peters O, Jessen F, Luckhaus C, Perneczky R, Jahn H, Fiszer M, Maler JM, Zimmermann R, Bruckmoser R, Kornhuber J, Lewczuk P. Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho-tau in patients with low- and high-CSF A\u03b240 load. J Neurochem. 2007;101(4):1053\u20139. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04404.x.","journal-title":"J Neurochem"},{"issue":"2","key":"817_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow K. Cerebrospinal fluid biomarkers for Alzheimer\u2019s disease. NeuroRx. 2004;1(2):213\u201325. https:\/\/doi.org\/10.1602\/neurorx.1.2.213.","journal-title":"NeuroRx."},{"issue":"3","key":"817_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith APL, Buckley CJ, McLain R, Salloway S. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287\u201394. https:\/\/doi.org\/10.1001\/jamaneurol.2014.4144.","journal-title":"JAMA Neurol."},{"issue":"7","key":"817_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jamaneurol.2020.0528","volume":"77","author":"AS Fleisher","year":"2020","unstructured":"Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 2020;77(7):829\u201339. https:\/\/doi.org\/10.1001\/jamaneurol.2020.0528.","journal-title":"JAMA Neurol"},{"key":"817_CR21","first-page":"346","volume":"10","author":"I Ill\u00e1n-Gala","year":"2018","unstructured":"Ill\u00e1n-Gala I, Pegueroles J, Montal V, Vilaplana E, Carmona-Iragui M, Alcolea D, et al. Challenges associated with biomarker-based classification systems for Alzheimer\u2019s disease. Alzheimers Dement Diagn Assess Dis Monit. 2018;10:346\u201357.","journal-title":"Alzheimers Dement Diagn Assess Dis Monit"},{"issue":"02","key":"817_CR22","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1055\/s-0034-1381734","volume":"34","author":"AM Grijalvo-Perez","year":"2014","unstructured":"Grijalvo-Perez AM, Litvan I. Corticobasal Degeneration. Semin Neurol. 2014;34(02):160\u201373. https:\/\/doi.org\/10.1055\/s-0034-1381734.","journal-title":"Semin Neurol"},{"issue":"3","key":"817_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, Naomi Kouri BS, Murray ME, Josephs KA. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci. 2011;45(3):384\u20139. https:\/\/doi.org\/10.1007\/s12031-011-9589-0.","journal-title":"J Mol Neurosci"},{"issue":"3","key":"817_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00702-018-01967-w","volume":"126","author":"S Selvackadunco","year":"2019","unstructured":"Selvackadunco S, Langford K, Shah Z, Hurley S, Bodi I, King A, Aarsland D, Troakes C, al-Sarraj S. Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. J Neural Transm. 2019;126(3):327\u201337. https:\/\/doi.org\/10.1007\/s00702-018-01967-w.","journal-title":"J Neural Transm"},{"key":"817_CR25","volume-title":"Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later","author":"CM Roe","year":"2013","unstructured":"Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Dreyfus DM, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. 2013."},{"key":"817_CR26","doi-asserted-by":"crossref","unstructured":"Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau\/\u03b2-amyloid 42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64(3):343\u20139.","DOI":"10.1001\/archneur.64.3.noc60123"},{"key":"817_CR27","volume-title":"CSF tau\/A\u03b242 ratio for increased risk of mild cognitive impairment: a follow-up study","author":"G Li","year":"2007","unstructured":"Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al. CSF tau\/A\u03b242 ratio for increased risk of mild cognitive impairment: a follow-up study. 2007."},{"key":"817_CR28","doi-asserted-by":"crossref","unstructured":"Ferreira D, Rivero-Santana A, Perestelo-P\u00e9rez L, Westman E, Wahlund LO, Sarr\u00eda A, et al. Improving CSF biomarkers\u2019 performance for predicting progression from mild cognitive impairment to Alzheimer\u2019s disease by considering different confounding factors: a meta-analysis. Front Aging Neurosci. 2014;6:287. Frontiers Media S.A.","DOI":"10.3389\/fnagi.2014.00287"},{"issue":"3","key":"817_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Hansson - 2006. Lancet Neurol. 2006;5(3):228\u201334. https:\/\/doi.org\/10.1016\/S1474-4422(06)70355-6.","journal-title":"Lancet Neurol"},{"key":"817_CR30","doi-asserted-by":"crossref","unstructured":"Degerman Gunnarsson M, Ingelsson M, Blennow K, Basun H, Lannfelt L, Kilander L. High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer\u2019s disease. Alzheimers Res Ther. 2016;8(1):22.","DOI":"10.1186\/s13195-016-0191-0"},{"issue":"14","key":"817_CR31","doi-asserted-by":"publisher","first-page":"E1567","DOI":"10.1212\/WNL.0000000000007248","volume":"92","author":"A Soldan","year":"2019","unstructured":"Soldan A, Pettigrew C, Fagan AM, Schindler SE, Moghekar A, Fowler C, Li QX, Collins SJ, Carlsson C, Asthana S, Masters CL, Johnson S, Morris JC, Albert M, Gross AL. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology. 2019;92(14):E1567\u201379. https:\/\/doi.org\/10.1212\/WNL.0000000000007248.","journal-title":"Neurology."},{"issue":"1","key":"817_CR32","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","volume":"95","author":"JL Ebenau","year":"2020","unstructured":"Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber A, Visser PJ, Prins ND, Sikkes SAM, Scheltens P, van Berckel BNM, van der Flier WM. ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology. 2020;95(1):e46\u201358. https:\/\/doi.org\/10.1212\/WNL.0000000000009724.","journal-title":"Neurology."},{"issue":"17","key":"817_CR33","doi-asserted-by":"publisher","first-page":"E1635","DOI":"10.1212\/WNL.0000000000008361","volume":"93","author":"D Altomare","year":"2019","unstructured":"Altomare D, De Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, et al. Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology. 2019;93(17):E1635\u201346. https:\/\/doi.org\/10.1212\/WNL.0000000000008361.","journal-title":"Neurology."},{"issue":"8","key":"817_CR34","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jalz.2017.01.015","volume":"13","author":"DR Roalf","year":"2017","unstructured":"Roalf DR, Moore TM, Mechanic-Hamilton D, Wolk DA, Arnold SE, Weintraub DA, Moberg PJ. Briding cognitive screening tests in neurological disorders: a cross-walk between s-MoCA and MMSE. Alzheimers Dement. 2017;13(8):947\u201352. https:\/\/doi.org\/10.1016\/j.jalz.2017.01.015.","journal-title":"Alzheimers Dement"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-021-00817-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-021-00817-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T12:36:46Z","timestamp":1618922206000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-021-00817-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["817"],"URL":"https:\/\/doi.org\/10.1186\/s13195-021-00817-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"2 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the Ethical Committee Research KU\/UZ Leuven.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}